Viewing Study NCT01561404



Ignite Creation Date: 2024-05-06 @ 12:24 AM
Last Modification Date: 2024-10-26 @ 10:49 AM
Study NCT ID: NCT01561404
Status: TERMINATED
Last Update Posted: 2015-04-28
First Post: 2012-03-20

Brief Title: Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise
Sponsor: Josep M Cruzado
Organization: Hospital Universitari de Bellvitge

Study Overview

Official Title: Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise
Status: TERMINATED
Status Verified Date: 2015-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: lack of potential patients
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: EXETOR
Brief Summary: This is an exploratory study based on the hypothesis that kidney transplant patients treated with an immunosuppressive therapy based on an inhibitor of the mammalian target of rapamycin m-TOR may increase resistance to physical exercise which would result in an improvement in the quality of life of these patients
Detailed Description: The hypothesis of the present study is that with respect to calcineurin inhibitors the mTOR inhibitor-based immunosuppression may alter the physical exercise capacity in renal transplant patients

This is based on recent data obtained Regarding metabolism there is evidence that inhibition of mTOR reduces muscle glucose utilization as well as increase fatty acid oxidation On the other hand has shown that drugs based on mTOR inhibitors in the context of excess of nutrients improves intracellular glucose uptake in skeletal muscle cells Through these mechanisms could increase resistance to physical exercise which would result in an improvement in the quality of life of patients Nevertheless there isnt any paper that has explored this hypothesis accurately

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2009-010541-31 EUDRACT_NUMBER None None